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OBJECTIVEdTo investigate the impact of iron status on survival in patients with type 2
diabetes and coronary artery disease (CAD).
RESEARCH DESIGN AND METHODSdSerum ferritin, transferrin saturation (Tsat),
and soluble transferrin receptor (sTfR) were measured in 287 patients with type 2 diabetes and
stable CAD (65 6 9 years of age, 78% men).
RESULTSdDuring a mean follow-up of 456 19 months, there were 59 (21%) deaths and 60
(21%) cardiovascular hospitalizations. Both serum ferritin and sTfR strongly predicted 5-year
all-cause mortality rates, independently of other variables (including hemoglobin, measures of
renal function, inﬂammation, and neurohormonal activation). There was an exponential rela-
tionship between sTfR and mortality (adjusted hazard ratio [HR] per 1 log mg/L: 4.24 [95% CI
1.43–12.58], P = 0.01), whereas the relationship between ferritin and mortality was U-shaped
(for the lowest and the highest quintiles vs. the middle quintile [reference group], respectively:
adjusted HR 7.18 [95% CI 2.03–25.46], P = 0.002, and adjusted HR 5.12 [1.48–17.73], P =
0.01). Similar patterns were observed for the composite outcome of all-cause mortality or car-
diovascular hospitalization, and in these multivariable models, low Tsat was related to unfavor-
able outcome.
CONCLUSIONSdBoth low and high serum ferritin (possibly reﬂecting depleted and exces-
sive iron stores, respectively) along with high serum sTfR (reﬂecting reduced metabolically
available iron) identify patients with type 2 diabetes and CAD who have a poor prognosis.
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The clinical signiﬁcance of deﬁciencyand disordered metabolism of ironin patients with chronic diseases
associated with aging (1), including obe-
sity (2), metabolic syndrome (3), coro-
nary artery disease (CAD) (4), and heart
failure (HF) (5–7), has received much at-
tention. Iron overload and associated ox-
idative stress have been reported to
accelerate the development of atheroscle-
rosis (8) and cause endocrine organ dys-
function (9). However, iron deﬁciency
(ID) is the most common dietary deﬁ-
ciency and the predominant cause of ane-
mia worldwide (10).
The physiological signiﬁcance of ID
may be much broader than its role in
erythropoiesis (1,7,11,12). Iron is also
critical for cellular energy generation by
mitochondria (13–15). ID will impair
the function of cells with high energy de-
mand whether due to mechanical work,
high metabolic rate, or high rates of
proliferation (11,12).
Diabetes may cause profound de-
rangements of energy metabolism due to
insulin resistance and mitochondrial dys-
function (16,17), contributing to a high
risk of fatal and nonfatal cardiovascular
events, and acting as an adjuvant sub-
strate for other factors interfering with en-
ergy metabolism, such as iron excess or
depletion. Attention has focused, until
now, on the unfavorable effects of iron
overload in diabetes, including oxidative
stress and hemochromatosis (9), with lit-
tle attention being paid to ID other than in
pregnancy (18).
Accordingly, we investigated the im-
pact of iron status assessed using circu-
lating biomarkers on survival in patients
with type 2 diabetes and CAD.
RESEARCH DESIGN AND
METHODS
Study cohort
Patients with type 2 diabetes and CAD
were recruited from outpatient clinics or
elective admissions at the Centre for Heart
Diseases, Military Hospital (Wroclaw,
Poland). Inclusion criteria were as follows:
1) type 2 diabetes according to the criteria
pointed out in The Task Force on Diabetes
and Cardiovascular Diseases of the Euro-
pean Society of Cardiology (ESC) and of
the European Association for the Study of
Diabetes (EASD) (19) of $6 months du-
ration; 2) a documented history of CAD
based on the ESC recommendations (19)
of$6 months duration, i.e., the presence
of signiﬁcant coronary artery lesions in
coronary angiography along with the
symptoms of stable angina, or a conﬁrmed
episode of myocardial infarction; and 3)
stable therapy for both type 2 diabetes
and CAD for$1month. Exclusion criteria
included the following: 1) acute coronary
syndrome and/or coronary revasculariza-
tion within the previous 3 months; 2) un-
planned hospitalization due to any other
cardiovascular reason within the previous
month; 3) any acute or chronic illness that
might inﬂuence iron metabolism (includ-
ing known malignancy, infection, severe
chronic kidney disease requiring dialysis,
and hematological diseases); 4) any treat-
ment for anemia or ID in the previous 12
months; and 5) lack of informed written
consent.
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When subjects were screened for this
study, they were asked in detail about
blood transfusions, erythropoietin ther-
apy, intravenous iron infusions, and any
nutritional supplements potentially con-
taining iron. None of subjects included in
the study received such a therapy. Addi-
tionally, all anemic subjects included into
the study underwent a routine clinical
evaluation in order to detect any potential
secondary causes of anemia. Patients with
evidence of active bleeding were not in-
cluded in the study. However, routine
endoscopy was not required.
The study protocol was approved by
the local ethics committees, and all sub-
jects gave written informed consent. The
study was conducted in accordance with
the Helsinki Declaration.
Indices of iron status and other
laboratory measurements assessed in
peripheral blood
Venous blood samples were taken in the
morning after an overnight fast and after a
supine rest of at least 15 min. Hemato-
logical measurements were assessed from
fresh venous blood anticoagulated with
EDTA. Hemoglobin (g/dL) was measured
using the ADVIA 120 automated system
(SiemensHealthcare Diagnostics, Deerﬁeld,
IL). Anemia was deﬁned as hemoglobin
,12 g/dL in women and ,13 g/dL in
men (20).
After centrifuging of heparinized and
clotted blood, supernatant plasma and
serum were stored frozen at –708C until
analyses for 1) serum ferritin (mg/L) mea-
sured using electrochemiluminescence
with the Elecsys 2010 System (Roche Di-
agnostics GmbH, Mannheim, Germany);
2) transferrin saturation (Tsat) calculated
as a ratio serum iron (mg/dL) and total
iron binding capacity (mg/dL) (multiplied
by 100 and expressed in percentage),
both assessed using a substrate method
with Feren S (Thermo Fisher Scientiﬁc,
Waltham, MA); and 3) serum soluble
transferrin receptor (sTfR, mg/L) mea-
sured using immunonephelometry (Sie-
mens Healthcare Diagnostics, Marburg,
Germany).
Plasma N-terminal protype B natri-
uretic peptide (NT-proBNP, pg/mL) was
measured using immunoassay based on
electrochemiluminescence on the Elecsys
1010/2010 System. Serum high-sensitivity
C-reactive protein (hsCRP, mg/L) was as-
sessed using kinetic nephelometry (Dade
Behring; Siemens Healthcare Diagnos-
tics, Deerﬁeld, IL). Renal function was
assessed using the estimated glomerular
ﬁltration rate (eGFR, mL/min/1.73 m2),
calculated from the Modiﬁcation of Diet
in Renal Disease equation (21).
HbA1c (%) was measured using an
immunochemical assay (AxSYM; Abbot
Laboratories, Abbot Park, IL). HbA1c
was expressed also in mmol/mol, after
being converted from percentage using
the NGSP’s HbA1c converter (http://
www.ngsp.org/convert1.asp). Insulin
resistance was estimated using the ho-
meostatic model assessment of insulin re-
sistance (HOMA-IR) from basal (fasting)
plasma glucose and insulin concentra-
tions (22) (calculated only for patients
not treated with insulin). Plasma glucose
(mg/dL) was assessed using a colorimetric
assay with glucose oxidase (Konelab
Prime 60i/30i; Thermo Fisher Scientiﬁc,
Waltham, MA). Plasma insulin (mIU/mL)
was measured using an immunochemilu-
minescence assay (Liason Insulin; DiaSorin
S.p.a., Saluggia, Italy).
Clinical follow-up
Patients were regularly seen by the study
investigators in outpatient clinics. Further
information regarding survival was ob-
tained directly from patients or their
relatives and the hospital system.
There were two predeﬁned end
points: 1) all-cause mortality and 2) the
ﬁrst event of either death or cardiovascu-
lar hospitalization (myocardial infarc-
tion, stroke, transient ischemic attack
[TIA], HF hospitalization, and coronary
revascularization).
There is no doubt that all-cause death
is commonly accepted as the most rele-
vant outcome end point. However, in
recent years, most outcome analyses per-
formed in patients at high risk of cardio-
vascular events also consider unplanned
cardiovascular hospitalizations as clini-
cally relevant end points. There is com-
pelling evidence that cardiovascular
hospitalization worsens the patient’s
quality of life, may be a trigger for disease
progression, and, in some cases, is also
associated with higher morbidity and
mortality during a longer follow-up. In
order to focus on those that are the most
relevant for diabetic patients with CAD
(considered as the population at the high-
est cardiovascular risk), we prospectively
decided to focus on the events pathophys-
iologically related to either atherothrom-
botic complications (myocardial infarction,
a need for coronary revascularization,
and stroke/TIA) or clinical evidence of
HF decompensation requiring hospital
admission.
The length of follow-up of patients
who did not experience any aforemen-
tioned event or who experienced any
event after 5 years was censored at
1,825 days (5 years).
Statistical analyses
Most continuous variables had a normal
distribution and were expressed as a
mean (x) (with an SD). The continuous
variables with a skewed distribution (the
duration of diabetes, plasma NT-proBNP,
serum hsCRP, eGFR, HOMA-IR, serum
ferritin, and serum sTfR) were expressed
as a median (with lower and upper quar-
tiles). Variables were log transformed as
necessary in order to normalize their
distribution, and log-transformed values
were used for further statistical analyses.
The intergroup differences in continuous
variables were tested using the Student
t test, whereas the relationships between
continuous variables were assessed using
the Pearson linear correlatory coefﬁcients.
Categorical variables were expressed as
the number of patients in given categories
(with a percentage). The intergroup differ-
ences in categorical variables were tested
using the x2 test.
The associations between iron status
(assessed using serum ferritin, Tsat, and
sTfR) and clinical variables and event-free
survival during the 5-year follow-up in
patients with type 2 diabetes and CAD
were established using Cox proportional
hazard regression analyses (both univari-
able and multivariable models). In the
univariable analyses, the following vari-
ables were included: age, sex, BMI, systolic
blood pressure (BP), the duration of di-
abetes (log), left ventricular ejection frac-
tion (LVEF), plasma NT-proBNP (log),
serum hsCRP (log), HOMA-IR (log),
HbA1c, eGFR (log), hemoglobin, and
iron status biomarkers (serum ferritin
[log], Tsat, and sTfR [log]). All variables,
which appeared to be signiﬁcant in
univariable Cox regression models,
were included in the multivariable Cox
regression models. All analyses were per-
formed twice, separately for two prede-
ﬁned end points (as described above).
For both univariable and multivariable
models, hazard ratios (HRs) (with 95%
CIs) with corresponding x2 and P values
were estimated for all variables incorpo-
rated into the models. The assumption of
the proportional hazard was tested for
each derived model.
For serum ferritin, Tsat, and sTfR,
nonlinear associations with event-free sur-
vival rates were expected. Tsat appeared
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to be linearly related to analyzed event
rates, but not serum ferritin or sTfR. In
order to assess the shape of association
between the later two iron status bio-
markers and event-free survival rates,
univariable and multivariable models
were constructed, where these variables
were included as 1) log transformed
and 2) transformed using natural cubic
splines with n knots (23). The number of
knots was chosen based on Akaike In-
formation Criterion for univariable
models (24). Serum ferritin was spline
transformed with three knots (demon-
strating U-shaped associations with
event-free survival rates), whereas sTfR
with two knots (demonstrating expo-
nential associations with event-free sur-
vival rates). The ﬁtness of the established
models was expressed using the x2 test
(with P values). Natural cubic splines are
well suited, because they allow estima-
tion of nonlinear relationships (23),
which were expected to exist in our
study population. As serum ferritin ap-
peared to have a U-shaped association
with event rates, it was categorized into
quintiles, with quintile 3 chosen as a ref-
erence group.
All statistical analyses were per-
formed using Statistica 9.1 and R version
2.15.2 (www.r-project.org) (25). The
P value,0.05 was considered statistically
signiﬁcant.
RESULTS
Baseline clinical characteristics
of patients with type 2 diabetes
and CAD
The baseline clinical characteristics of 287
patients with type 2 diabetes and CAD are
shown in Table 1, overall and by quintile
of serum ferritin (quintile 1,,60.9 mg/L;
quintile 2, 60.9–118.9 mg/L; quintile 3,
119.0–202.1 mg/L [reference group];
quintile 4, 202.2–304.8 mg/L; quintile 5,
$304.9 mg/L). Among all investigated di-
abetic patients with CAD, 260 (91%of all)
underwent coronary angiography, and in
these patients, the one-, two- and three-
vessel disease was found in 97 (37%), 75
(29%), and 88 (34%) subjects, respectively
(percentage of those with performed coro-
nary angiography). Additionally, 143
(55%) of those who underwent coronary
angiography also experienced myocardial
infarction in the past. All remaining pa-
tients who did not undergo coronary angi-
ography (27, 9% of all) had a conﬁrmed
episode of myocardial infarction in the
past.
Iron status and clinical
characteristics of patients with type 2
diabetes and CAD
Patients in the lowest compared with the
middle quintile of serum ferritin were
older; had higher systolic BP, longer dura-
tion of diabetes, lower hemoglobin, and
more anemia; and were more frequently
treated with sulphonylureas (all P, 0.05)
(Table 1). Patients in the highest compared
with the middle quintile of serum ferritin
had lower LVEF and higher plasma NT-
proBNP, were more likely to be men and
have anemia, andwere less frequently treated
with ACE inhibitors or/and angiotensin re-
ceptor blockers (all P, 0.05) (Table 1).
Low Tsat was associated with older
age, high plasmaNT-proBNP, high serum
hsCRP, and low hemoglobin (linear/log-
linear relationships with P , 0.05). Low
Tsat was also found in anemic patients;
those treated with aldosterone antago-
nists, diuretics, and anticoagulant drugs;
and those not receiving any antiplatelet
drug (all P , 0.05) (Table 1). In a multi-
variable stepwise regression model, only
serum hsCRP, plasma NT-proBNP, he-
moglobin, and treatment with aldoste-
rone antagonists were associated with
Tsat (all P , 0.05).
High serum sTfR was associated with
low LVEF, high plasma NT-proBNP, and
high serum hsCRP (log-linear relation-
ships with P , 0.05). High serum sTfR
was also found in anemic patients andwas
associated with several treatments (all P,
0.05) (Table 1). In a multivariable step-
wise regression model, only plasma NT-
proBNP, serum hsCRP, the presence of
anemia, therapy with aldosterone antago-
nists, and lack of therapy with a statin
were associated with sTfR (all P , 0.05).
Mutual relationships between
indices of iron status in patients
with type 2 diabetes and CAD
Tsat was inversely related to serum sTfR
(r = 20.35, P , 0.001) and positively to
serum ferritin (r = 0.48, P , 0.001) (both
log-linear relationships), and there was a
weak inverse relationship between serum
ferritin and sTfR (r = 20.17, P , 0.01).
Patients in the lowest and highest quintiles
of serum ferritinwere characterized byhigh
serum sTfR compared with patients in the
middle ferritin quintile (both P , 0.01).
Iron status and risk of death
in patients with type 2 diabetes
and CAD
The mean follow-up in a whole cohort
was 1,356 6 578 days (median 1,692
days, range 1–1,825 days), and the
mean follow-up for survivors was
1,546 6 438 days (median 1,825 days,
range 365–1,825 days). By 5 years, 59
patients (21%) had died, and the mean
time to death was 621 6 455 days (me-
dian 577 days, range 1–1,587 days).
The proportionality assumption and
the assumption of a log-linear relation-
ship between the continuous variables
and the hazard function were fulﬁlled,
except for serum ferritin.
Univariable models. In univariable Cox
proportional hazard regression models,
the following variables predicted an in-
creased 5-year mortality: low LVEF, high
plasma NT-proBNP (log), high serum
hsCRP (log), reduced eGFR (log) (all
P, 0.05), and borderline reduced hemo-
globin (P = 0.06) (Table 2). Low Tsat and
high serum sTfR (log) were also associ-
ated with an increased 5-year mortality,
and the Cox proportional hazard regres-
sion models of the spline-transformed se-
rum ferritin with three knots and the
spline-transformed serum sTfR with two
knots were also statistically signiﬁcant (all
P , 0.001) (Table 2). When serum ferri-
tin was expressed in quintiles, patients in
the middle quintile had the most favor-
able outcome compared with both the
lowest and highest quintiles (both P ,
0.01) (Table 2).
Multivariable models. In multivariable
models, serum sTfR (both when log and
spline transformed) and serum ferritin
(both when expressed in quintiles and
when spline transformed), but not Tsat,
predicted all-cause mortality (all P #
0.05) (Table 2). The relationship between
serum ferritin and mortality remained U-
shaped (Fig. 1A), whereas the relation-
ship between serum sTfR and mortality
was exponential (Fig. 1B).
Iron status and risk of death
or cardiovascular hospitalization
in patients with type 2 diabetes
and CAD
The mean follow-up free of cardiovascu-
lar hospitalization or death in a whole
cohort was 1,162 6 636 days (median
1,278 days, range 1–1,825 days), and
the mean follow-up for those who did
not experience any predeﬁned event
(death or cardiovascular hospitalization)
was 1,538 6 433 days (median 1,825
days, range 365–1,825 days). By 5 years,
112 patients (39%) had experienced car-
diovascular hospitalization (including 21
HF hospitalizations, 18 coronary revascu-
larizations, 15 myocardial infarctions,
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and 6 stroke/TIA) or had died, and the
mean time to the ﬁrst predeﬁned event
was 576 6 423 days (median 524 days,
range 1–1,659 days).
Univariable models. In univariable Cox
proportional hazard regression models,
the following variables predicted an in-
creased risk of death or cardiovascular
hospitalization: high plasma NT-proBNP
(log), high serum hsCRP (log), reduced
eGFR (log), and reduced hemoglobin (all
P, 0.05). Low Tsat and high serum sTfR
(log) were associated with increased rates
of death or cardiovascular hospitalization,
and the Cox proportional hazard regres-
sion models of the spline-transformed se-
rum ferritin with three knots and the
spline-transformed serum sTfR with two
knots were also statistically signiﬁcant (all
P , 0.001) (Table 2). When serum ferri-
tin was expressed in quintiles, patients
with serum ferritin in the middle quintile
had the most favorable outcome com-
paredwith those in the lowest and highest
quintiles (both P , 0.01) (Table 2).
Multivariable models. In multivariable
models, serum sTfR (both when log and
spline transformed), serum ferritin (both
when expressed in quintiles and when
spline transformed), and Tsat were asso-
ciated with death or cardiovascular hos-
pitalization (all P , 0.05) (Table 2). The
relationship between serum ferritin and
outcome was again U-shaped (Fig. 1D),
but those for serum sTfR and Tsat were
exponential (Fig. 1E) and linear (Fig. 1F),
respectively.
CONCLUSIONSdWe have demon-
strated that measures of iron status pre-
dict long-term outcome in patients with
type 2 diabetes and clinically overt CAD,
even after adjusting for conventional
(e.g., age, sex, and renal function) and
some more advanced (e.g., hsCRP and
NT-proBNP) prognostic markers.
We deliberately assessed three differ-
ent markers of iron status. Ferritin is the
major intracellular protein storing iron
(26), and serum concentrations,30 mg/L
are speciﬁc for absolute ID (27). How-
ever, serum ferritin is commonly elevated
when inﬂammatory pathways are acti-
vated, including atherosclerosis and renal
dysfunction (27,28). A normal serum fer-
ritin may be misleading. Extremely high
serum ferritin (.1,000 mg/L) indicates a
high probability of hemochromatosis
(29). Importantly, high circulating ferri-
tin provides no insight about the amount
of intracellular iron available for meta-
bolic (including energetic) needs (26).T
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Tsat is a direct measure of the circulating
iron pool, but it is unclear if this reﬂects
the amount in peripheral tissues (27,28).
Transferrin receptor is the major entrance
pathway for iron to most hematopoietic
and extrahematopoietic cells (26). When
cells become deﬁcient in iron for meta-
bolic processes (mainly in mitochondria),
this particle is overexpressed on the cellu-
lar membrane and shed into the circula-
tion, and thus, high circulating sTfR
reﬂects intracellular iron depletion
(30,31). We found only moderate (at the
most) associations between Tsat and se-
rum ferritin and sTfR. Importantly, pa-
tients with both low and high serum
ferritin had increased circulating sTfR.
There are two possible explanations for cel-
lular ID in the presence of high serum fer-
ritin. It is possible that in patients with
more advanced disease, an inﬂammatory
state exists, causing serum ferritin to rise
despite cellular ID. Alternatively, it is pos-
sible that tissue stores of iron are high but
not metabolically available for hematopoe-
sis or other cell functions, or even that iron
overload causes an inﬂammatory response.
We found no major associations be-
tween iron indices and measures of glu-
cose control or the severity of insulin
resistance in patients with type 2 diabetes
and CAD. Relationships between low
serum ferritin and high HbA1c have
been reported by some authors in young
adults (32) and a small group of pregnant
women with type 2 diabetes (18). Such
differences may more reﬂect the presence
of advanced and complex cardiovascular
disease (CVD) in our patients (59% with
previous myocardial infarction and 26
and 30% with two- and three-vessel dis-
ease, respectively), the larger population
studied, or the greater array of measure-
ments included in ourmultivariable mod-
els. In contrast, we have demonstrated
associations between markers of iron sta-
tus and measures of the severity of CVD
(i.e., plasma NT-proBNP and LVEF) and
of inﬂammation (serumhsCRP)most likely
related to the burden of atherosclerotic
disease.
For the ﬁrst time, we have shown in
patients with type 2 diabetes and clini-
cally overt CAD that ID, expressed as both
depleted iron stores and as diminished
iron available for metabolic needs, criti-
cally impairs homeostasis in general, and
markedly worsens prognosis. Circulating
biomarkers of iron status allow the pre-
diction of the long-term follow-up (5
years), and the discriminative value of
these parameters has also been observed
as early as after 3–6 months of clinical
follow-up (data not shown). The relation-
ships with outcomes have been demon-
strated to be linear for Tsat, U-shaped for
serum ferritin, and exponential for sTfR
(Fig. 1).
Available evidence linking iron status
and cardiovascular morbidity and mor-
tality is equivocal. Regarding cardiovas-
cular morbidity, the analysis of 2,874
subjects from the Monitoring of Trends
and Determinants in Cardiovascular Dis-
ease (DAN-MONICA) I study revealed no
links between serum ferritin and the risk
of either CVD or CAD during the 10-year
follow-up (33). However, in two studies
performed in elderly subjects $65 (34)
and$71 years of age (35), low circulating
iron was independently associated with
the higher occurrence of CVD and CAD
during the long-term follow-up. Also, in
an unselected cohort of 906 women
(mean age 61 6 17 years), low nonheme
(but not heme) iron intake assessed based
on a questionnaire was related to the in-
creased rates of nonfatal cerebrovascular
and coronary events during the 10-year
follow-up (36). Finally, among .5,000
Figure 1dSerum ferritin, serum sTfR, and Tsat by relative hazard of events (all-cause deaths [A–C]; all-cause deaths and cardiovascular hos-
pitalizations [D–F]) using cubic splines during the 5-year follow-up in diabetic patients with CAD.
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subjects 45–74 years of age free of stroke
at baseline from the ﬁrst National Health
and Nutrition Examination Survey
(NHANES I) Epidemiologic Followup
Study, there was a U-shaped relationship
between Tsat (high and low) and the risk
of incident stroke in women (but not in
men) during the 12-year follow-up (37).
The results of studies that investi-
gated the associations between iron status
and survival are even more heteroge-
neous. There is evidence established in
general populations on the associations
between increased all cause-mortality and
low circulating iron (34,35) and low Tsat
(38,39), between high cardiovascular
mortality and low Tsat (38,39), and be-
tween high mortality due to CAD and low
Tsat (40). However, the other authors
have not conﬁrmed the links between
mortality rates and different indices of
iron status, including Tsat and serum fer-
ritin (38,41–43). Finally, among 6,102
women 45–64 years of age without
known heart disease at baseline, there
was the U-shaped relationship between
Tsat and mortality due to CAD during
the 12-year follow-up (44). Among an
unselected population of 906 women
(mean age 61 6 17 years), low nonheme
(but not heme) iron intake assessed based
on a questionnaire increased the risk of
fatal cerebrovascular and coronary events
during the 10-year follow-up (36). On the
other hand, among.25,000 healthy men
40–79 years of age, free of stroke, CAD,
and cancer at baseline, dietary iron intake
assessed based on a questionnaire was
positively associated with the higher mor-
tality from both stroke and CAD (45).
There is also an observation from the
NHANES II that individuals with high
Tsat (.55%) and high LDL cholesterol
(.160 mg/dL) had markedly increased
both CVD mortality and all-cause mortal-
ity (46). In a recent study, high circulating
catalytic iron (not bound to either trans-
ferrin or ferritin) in 1,701 patients with
acute coronary syndromes has been
shown to predict increased all-cause mor-
tality during the median 10-month follow-
up, but without any associations with
further cardiovascular nonfatal events,
such us recurrent ischemia, myocardial
infarction, and HF (47). Finally, it has
been shown that in patients with HF,
ID is strongly and independently asso-
ciated with high mortality during the
long-term follow-up, in those with and
without anemia, with and without CAD,
and with and without systolic dysfunc-
tion (5,48,49).
We acknowledge the observational
character of our study, which was not
designed to investigate either the cause of
abnormal iron status or the mechanisms
linking iron disorder to poor outcomes.
The observed associations between serum
measures of ID other than ferritin and
high hsCRP suggest that inﬂammation
could interfere with iron metabolism, as it
has been shown in chronic kidney disease
(28,50) but not in HF (48). Another po-
tential explanation linking abnormal iron
status and outcomes in these patients
could be the fact that iron is a micronu-
trient crucial for the cellular metabolism
and survival involved in numerous bio-
chemical reactions, including oxygen
storage and transport, oxidative metabo-
lism and mitochondrial functioning, and
turnover of lipids, proteins, and ribonu-
cleic acids, and there are premises that
both ID and iron excess may negatively
affect the efﬁcacy of these reactions
(7,11–15). These theories deserve further
studies. Ultimately, studies of iron sup-
plementation, e.g., in patients with HF
(51,52), ideally showing only those with
ID beneﬁt, and of iron depletion in those
with possible iron overload are required
to determine the real functional signiﬁ-
cance of perceived abnormalities. A major
impediment to research in this area is de-
ﬁning the precise biochemical criteria by
which to deﬁne ID and iron overload. Ex-
isting standard laboratory ranges may
only be an approximate guide.
In conclusion, both low and high
serum ferritin along with high serum
sTfR identify patients with type 2 diabetes
and clinically overt CAD who have a poor
prognosis. Additionally, patients with
low Tsat have an increased risk of death
or cardiovascular hospitalization during
long-term follow-up. If the primary in-
tention of assessing iron status is to detect
ID, then sTfR alone may be preferred.
However, measurement of serum ferritin
appears to add prognostic information.
These hypotheses require veriﬁcation in
prospective studies.
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